Key result
Becker muscular dystrophy shows elevated miR-206 and steroid-linked differences in myostatin expression.
Why the study?
Becker muscular dystrophy presents with highly variable clinical phenotypes and progression, prompting evaluation of circulating biomarkers alongside muscle MRI as noninvasive biological indicators of prognosis and disease monitoring.
Observational (n=8)
Circulating microRNAs and myostatin protein levels show potential as biomarkers for monitoring disease progression and management in Becker muscular dystrophy.
This is the authors' abstract. We don't add key points for this paper.
Becker muscular dystrophy (BMD) is an X-linked recessive disorder caused by dystrophin gene mutations. The phenotype and evolution of this muscle disorder are extremely clinical variable. In the last years, circulating biomarkers have acquired remarkable importance in their use as noninvasive biological indicators of prognosis and in monitoring muscle disease progression, especially when associated to muscle MRI imaging. We investigated the levels of circulating microRNAs (myo-miRNAs and inflammatory miRNAs) and of the proteins follistatin (FSTN) and myostatin (GDF-8) and compared results with clinical and radiological imaging data. In eight BMD patients, including two cases with evolving lower extremity weakness treated with deflazacort, we evaluated the expression level of 4 myo-miRNAs (miR-1, miR-206, miR-133a, and miR-133b), 3 inflammatory miRNAs (miR-146b, miR-155, and miR-221), FSTN, and GDF-8 proteins. In the two treated cases, there was pronounced posterior thigh and leg fibrofatty replacement assessed by muscle MRI by Mercuri score. The muscle-specific miR-206 was increased in all patients, and inflammatory miR-221 and miR-146b were variably elevated. A significant difference in myostatin expression was observed between steroid-treated and untreated patients. This study suggests that microRNAs and myostatin protein levels could be used to better understand the progression and management of the disease.
Answers are grounded in this paper and cite their sources.
May support miR-206 and myostatin as candidate biomarkers in Becker muscular dystrophy; hypothesis-generating and requires validation before clinical use.
No takes yet. Share an insight, caveat, or question.
Marozzo et al. (2020) conducted an observational in Becker muscular dystrophy (n=8). Evaluation of circulating microRNAs, follistatin, and myostatin vs. Steroid-treated vs untreated patients was evaluated on Expression levels of myo-miRNAs, inflammatory miRNAs, FSTN, and GDF-8 proteins. In patients with Becker muscular dystrophy, muscle-specific miR-206 was increased, and a significant difference in myostatin expression was observed between steroid-treated and untreated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: